Fluoxetine Is a Potent Inhibitor of Coxsackievirus Replication

Zuo, Jun; Quinn, Kevin K.; Kye, Steve; Cooper, Peter; Damoiseaux, Robert; Krogstad, Paul

doi:10.1128/aac.00983-12

Cited by 86 publications

(86 citation statements)

References 43 publications

(36 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the present report, the viral replication was indirectly demonstrated using fluoxetine, a chemical which inhibits the synthesis of negative-strand RNAs by either interfering with 2C protein activity or the rearrangement of cellular membranes by the viral 2BC or 3A proteins (Zuo et al, 2012). Our results showed detectable EmGFP in untreated cells and demonstrated a significant EmGFP signal reduction in the presence of fluoxetine.…”

Section: Discussionsupporting

confidence: 51%

“…Viral RNAs were transfected in the presence of two different concentrations (5 M and 10 M) of fluoxetine, an inhibitor of enterovirus replication (Zuo et al, 2012). No notable cytotoxicity was observed in mock-transfected cells.…”

Section: Rna Replication and Production Of Infectious Viral Particlesmentioning

confidence: 99%

“…Fluoxetine is a selective serotonin reuptake inhibitor, which has been shown to inhibit enterovirus replication (Zuo et al, 2012). Fluoxetine chlorhydrate 20 mg/5 ml oral solution (ARROW) was used in this assay.…”

Section: Replication Inhibition Assaymentioning

confidence: 99%

See 2 more Smart Citations

Construction of a subgenomic CV-B3 replicon expressing emerald green fluorescent protein to assess viral replication of a cardiotropic enterovirus strain in cultured human cells

Wehbe

Huguenin

Lévêque

et al. 2016

Journal of Virological Methods

View full text Add to dashboard Cite

a b s t r a c tCoxsackieviruses B (CV-B) (Picornaviridae) are a common infectious cause of acute myocarditis in children and young adults, a disease, which is a precursor to 10-20% of chronic myocarditis and dilated cardiomyopathy (DCM) cases. The mechanisms involved in the disease progression from acute to chronic myocarditis phase and toward the DCM clinical stage are not fully understood but are influenced by both viral and host factors. Subgenomic replicons of CV-B can be used to assess viral replication mechanisms in human cardiac cells and evaluate the effects of potential antiviral drugs on viral replication activities. Our objectives were to generate a reporter replicon from a cardiotropic prototype CV-B3/28 strain and to characterize its replication properties into human cardiac primary cells. To obtain this replicon, a cDNA plasmid containing the full CV-B3/28 genome flanked by a hammerhead ribozyme sequence and an MluI restriction site was generated and used as a platform for the insertion of sequences encoding emerald green fluorescent protein (EmGFP) in place of those encoding VP3. In vitro transcribed RNA from this plasmid was transfected into HeLa cells and human primary cardiac cells and was able to produce EmGFP and VP1-containing polypeptides. Moreover, non-structural protein biological activity was assessed by the specific cleavage of eIF4G1 by viral 2Apro . Viral RNA replication was indirectly demonstrated by inhibition assays, fluoxetine was added to cell culture and prevented the EmGFP synthesis. Our results indicated that the EmGFP CV-B3 replicon was able to replicate and translate as well as the CV-B3/28 prototype strain. Our EmGFP CV-B3 replicon will be a valuable tool to readily investigate CV-B3 replication activities in human target cell models.

show abstract

Section: Discussionsupporting

confidence: 51%

Section: Rna Replication and Production Of Infectious Viral Particlesmentioning

confidence: 99%

See 1 more Smart Citation

Construction of a subgenomic CV-B3 replicon expressing emerald green fluorescent protein to assess viral replication of a cardiotropic enterovirus strain in cultured human cells

Wehbe

Huguenin

Lévêque

et al. 2016

Journal of Virological Methods

View full text Add to dashboard Cite

show abstract

“…There are reports of query 3 (fluoxetine) for therapeutic uses other than antidepressants. Fluoxetine has been found to inhibit Coxsackievirus Replication [29], as well as hepatitis C virus [30], that matches with the presence of an antiviral target as Rank 2.…”

Section: Resultsmentioning

confidence: 92%

Inverse Virtual Screening in Drug Repositioning: Detailed Investigation and Case Studies

Warrier

Kharkar

2016

Crystallizing Ideas – The Role of Chemistry

View full text Add to dashboard Cite

Inverse virtual screening is a useful tool for drug repositioning or repurposing. The utility of this tool lies in the identification of potential targets for small-molecule ligands. With reference to drug repositioning, approved/existing small-molecule drugs can be processed by inverse virtual screening for the discovery of potential new molecular targets for such drugs. Both the ligand-and structure-based approaches can be used for the in silico screening. PharmMapper is a web-based tool for ligand-based inverse screening that employs pharmacophore mapping approach and identifies potential target candidates for small molecules. The present study demonstrates the usefulness of this approach for computational repositioning of approved/existing drugs. Here, query molecules belonging to protein kinase inhibitors, monoamine transporter inhibitors and G protein-coupled receptor antagonists were used. The results revealed potential novel molecular targets for the query molecules. Detailed literature search involving the query molecule-novel target pair led to interesting findings. The book chapter summarizes the interesting outcomes of the ligand-based inverse virtual screening.

show abstract

“…SSRI alters hepatic lipid biosynthesis (McIntyre et al, 2010), has an anti-inflammatory property (Tynan et al, 2012), and affects negatively MAPK or STAT-1 signals (Tsao et al, 2012). Moreover, SSRI acts as a suppressor to infectivity and replication of human immunodeficiency virus (HIV) (Benton et al, 2010) and is a potent inhibitor of enterovirus replication (Ulferts et al, 2013;Zuo et al, 2012); however, it is not clear whether the presence of SSRI can affect anti-HCV treatment.…”

Section: Introductionmentioning

confidence: 99%

Fluoxetine a novel anti-hepatitis C virus agent via ROS-, JNK-, and PPARβ/γ-dependent pathways

Young

Bai

et al. 2014

Antiviral Research

View full text Add to dashboard Cite

Fluoxetine Is a Potent Inhibitor of Coxsackievirus Replication

Cited by 86 publications

References 43 publications

Construction of a subgenomic CV-B3 replicon expressing emerald green fluorescent protein to assess viral replication of a cardiotropic enterovirus strain in cultured human cells

Construction of a subgenomic CV-B3 replicon expressing emerald green fluorescent protein to assess viral replication of a cardiotropic enterovirus strain in cultured human cells

Inverse Virtual Screening in Drug Repositioning: Detailed Investigation and Case Studies

Fluoxetine a novel anti-hepatitis C virus agent via ROS-, JNK-, and PPARβ/γ-dependent pathways

Contact Info

Product

Resources

About